On Friday, Lyell Immunopharma Inc (NASDAQ: LYEL) opened lower -11.37% from the last session, before settling in for the closing price of $0.76. Price fluctuations for LYEL have ranged from $0.75 to $3.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 428.28% over the last five years. Company’s average yearly earnings per share was noted 14.52% at the time writing. With a float of $144.26 million, this company’s outstanding shares have now reached $256.56 million.
The firm has a total of 224 workers. Let’s measure their productivity. In terms of profitability, gross margin is -23680.95%, operating margin of -348844.44%, and the pretax margin is -323792.06%.
Lyell Immunopharma Inc (LYEL) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lyell Immunopharma Inc is 50.62%, while institutional ownership is 21.59%.
Lyell Immunopharma Inc (LYEL) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 14.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.90% during the next five years compared to -15.28% drop over the previous five years of trading.
Lyell Immunopharma Inc (NASDAQ: LYEL) Trading Performance Indicators
Check out the current performance indicators for Lyell Immunopharma Inc (LYEL). In the past quarter, the stock posted a quick ratio of 13.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2908.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.80, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.83 in one year’s time.
Technical Analysis of Lyell Immunopharma Inc (LYEL)
Analysing the last 5-days average volume posted by the [Lyell Immunopharma Inc, LYEL], we can find that recorded value of 1.64 million was better than the volume posted last year of 1.04 million. As of the previous 9 days, the stock’s Stochastic %D was 5.10%. Additionally, its Average True Range was 0.10.
During the past 100 days, Lyell Immunopharma Inc’s (LYEL) raw stochastic average was set at 2.41%, which indicates a significant decrease from 6.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.68% in the past 14 days, which was lower than the 105.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0556, while its 200-day Moving Average is $1.7287. Now, the first resistance to watch is $0.7402. This is followed by the second major resistance level at $0.8067. The third major resistance level sits at $0.8531. If the price goes on to break the first support level at $0.6273, it is likely to go to the next support level at $0.5809. Should the price break the second support level, the third support level stands at $0.5144.
Lyell Immunopharma Inc (NASDAQ: LYEL) Key Stats
There are currently 292,162K shares outstanding in the company with a market cap of 174.49 million. Presently, the company’s annual sales total 130 K according to its annual income of -234,630 K. Last quarter, the company’s sales amounted to 30 K and its income totaled -44,580 K.
